Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$28.35 USD
-1.62 (-5.41%)
Updated Feb 3, 2025 04:00 PM ET
After-Market: $28.28 -0.07 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GPCR 28.35 -1.62(-5.41%)
Will GPCR be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Other News for GPCR
SA Asks: What's the most attractive weight-loss stock right now?
Metsera sees stock rally 54% following $275M IPO
Structure Therapeutics Inc (GPCR) Announces Participation in Upcoming Healthcare Conferences
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Piper Sandler
Novo Nordisk's Ozempic gets FDA approval for kidney disease